Ken S. Wong, PharmD, MPH
Faculty Directory

Ken S. WongPharmD, MPH

Ken S. WongPharmD, MPH

Director, Division of Healthcare and Biopharmaceutical Business &
Associate Professor of Pharmaceutical and Health Economics

Department of Pharmaceutical and Health Economics

Ken Wong is Director of the USC Mann Division of Healthcare and Biopharmaceutical Business. The Division consists of the Healthcare Decision Analysis and Biopharmaceutical Marketing graduate programs. Dr. Wong serves as an Associate Professor in the Department of Pharmaceutical and Health Economics and is a Senior Fellow at the USC Leonard D. Schaeffer Center for Health Policy & Economics.

He previously served as director of health economics and outcomes research and director of managed healthcare at Novartis Pharmaceuticals. Prior to his work in the pharmaceutical industry, he held pharmacy leadership positions at Cigna, Caremark, HealthNet and UniHealth. He served as an accreditation surveyor for the Joint Commission, where he surveyed and advised healthcare systems on pharmaceutical and quality of care standards.

He graduated from the University of Southern California with a Doctorate in Pharmacy and received his Master’s in Public Health from the University of Massachusetts at Amherst, and Bachelor’s degree from the University of California at Los Angeles.

Dr. Wong’s research interests include innovations in market access and drug pricing.

Areas of Expertise

  • Innovative Care Delivery Models
  • Health Economics & Outcomes Research
  • Managed Care
  • Market Access & Reimbursement
  • Innovative Pricing Models
  • Education

    University of Southern California


    University of Massachusetts at Amherst


    University of California at Los Angeles

    Bachelor of Arts

  • Links
  • Selected Articles

    Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective

    Journal of Managed Care & Specialty Pharmacy
    Frois C, Howe A, Jarvis J, Grice K, Wong K, Zacker C, Sasane R.

    2019 The U.S. health care system's transition to a value-based reimbursement model holds important implications for medical innovation, care delivery, and value-based assessments of therapeutic interventions. This transition has been especially noteworthy in oncology, with substantial ongoing changes to payer reimbursement and the provider landscape, as well as the introduction of value frameworks to guide drug treatment decision making. The implications of these changes for provider assessments of drug value and evidence needs remain unclear.

    Read More

    Impact of care management processes and integration of care on blood pressure control in diabetes.

    BMC Family Practice
    Wong K, Boulanger L, Smalarz A, Wu N, Fraser K, Wogen J.

    2013 Fragmentation within health care systems may negatively impact the quality of chronic disease patient care. We sought to evaluate the relationship between care management processes (CMP), integration of services, and blood pressure (BP) control among diabetic patients.

    Read More

    Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD

    Current Medical Research and Opinion
    Thornton Snider J, Luna Y, Wong KS, Zhang J, Chen SS, Gless PJ, Goldman DP.

    2012 To determine the association between inhaled corticosteroid (ICS) use and the risk of pneumonia among Medicare patients with chronic obstructive pulmonary disease (COPD).

    Read More

  • Affiliations
    • Novartis Pharmaceuticals

    • Joint Commission